On February 27, 2026, The FDA Issued Complete Response Letter For The Supplemental Biologics License Application For Zynyz; CRL Cites Catalent Indiana Regulatory Compliance As Sole Approvability Issue

On February 27, 2026, the FDA issued a Complete Response Letter (CRL) regarding the Supplemental Biologics License Application for Zynyz, indicating that the sole issue preventing approval was related to regulatory compliance at Catalent Indiana. This development may impact the stock performance of Incyte Corporation (ticker: INCY) as it seeks to address the compliance concerns raised by the FDA.